This company has been marked as potentially delisted and may not be actively trading. NASDAQ:VERV Verve Therapeutics (VERV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Verve Therapeutics Stock (NASDAQ:VERV) Get Verve Therapeutics alerts:Sign Up Key Stats Today's Range$11.13▼$11.1350-Day Range$10.91▼$11.3852-Week Range$3.89▼$11.41VolumeN/AAverage Volume4.91 million shsMarket Capitalization$992.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Read More Receive VERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VERV Stock News HeadlinesGoodbye daily statins? VERVE-102 aims to cut LDL cholesterol in one shotJune 8, 2026 | msn.comBig pharma all-in on gene therapy after obesity successMay 31, 2026 | msn.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.July 9 at 1:00 AM | InvestorPlace (Ad)A one-time experimental treatment might control cholesterol for lifeMay 29, 2026 | msn.comLilly says gene editing therapy cut “bad” cholesterol in early-stage trialMay 26, 2026 | seekingalpha.comLilly is looking for its next act beyond the weight-loss boomMay 26, 2026 | msn.comLilly says gene editing therapy cut bad cholesterol in early-stage trialMay 26, 2026 | msn.comLilly advances gene therapy, snaps up vaccine makers. It’s looking beyond weight lossMay 26, 2026 | msn.comSee More Headlines VERV Stock Analysis - Frequently Asked Questions How were Verve Therapeutics' earnings last quarter? Verve Therapeutics, Inc. (NASDAQ:VERV) announced its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.36. The company earned $32.98 million during the quarter, compared to the consensus estimate of $7.13 million. Verve Therapeutics had a negative net margin of 303.64% and a negative trailing twelve-month return on equity of 35.81%. When did Verve Therapeutics IPO? Verve Therapeutics (VERV) raised $239 million in an initial public offering on Wednesday, June 16th 2021. The company issued 14,035,789 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair served as the underwriters for the IPO. What other stocks do shareholders of Verve Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verve Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings5/14/2025Today7/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 VERV's financial health is in the Green zone, according to TradeSmith. VERV has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VERV CIK1840574 Webvervetx.com Phone617-603-0070FaxN/AEmployees110Year Founded2018Profitability EPS (Trailing Twelve Months)($2.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$198.71 million Net Margins-303.64% Pretax Margin-303.10% Return on Equity-35.81% Return on Assets-27.57% Debt Debt-to-Equity RatioN/A Current Ratio9.84 Quick Ratio9.84 Sales & Book Value Annual Sales$32.33 million Price / Sales30.69 Cash FlowN/A Price / Cash FlowN/A Book Value$5.83 per share Price / Book1.91Miscellaneous Outstanding Shares89,140,000Free Float71,938,000Market Cap$992.13 million OptionableOptionable Beta2.23 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:VERV) was last updated on 7/9/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VERV Stock Alerts